Display options
Cite
de Sola S, de la Torre R, Sánchez-Benavides G, et al. A new cognitive evaluation battery for Down syndrome and its relevance for clinical trials. Front Psychol. 2015;6:708doi: 10.3389/fpsyg.2015.00708.
de Sola, S., de la Torre, R., Sánchez-Benavides, G., Benejam, B., Cuenca-Royo, A., Del Hoyo, L., Rodríguez, J., Catuara-Solarz, S., Sanchez-Gutierrez, J., Dueñas-Espin, I., Hernandez, G., Peña-Casanova, J., Langohr, K., Videla, S., Blehaut, H., Farre, M., Dierssen, M. (2015). A new cognitive evaluation battery for Down syndrome and its relevance for clinical trials. Frontiers in psychology, 6708. https://doi.org/10.3389/fpsyg.2015.00708
de Sola, Susana, et al. "A new cognitive evaluation battery for Down syndrome and its relevance for clinical trials." Frontiers in psychology vol. 6 (2015): 708. doi: https://doi.org/10.3389/fpsyg.2015.00708
de Sola S, de la Torre R, Sánchez-Benavides G, Benejam B, Cuenca-Royo A, Del Hoyo L, Rodríguez J, Catuara-Solarz S, Sanchez-Gutierrez J, Dueñas-Espin I, Hernandez G, Peña-Casanova J, Langohr K, Videla S, Blehaut H, Farre M, Dierssen M. A new cognitive evaluation battery for Down syndrome and its relevance for clinical trials. Front Psychol. 2015 Jun 04;6:708. doi: 10.3389/fpsyg.2015.00708. eCollection 2015. PMID: 26089807; PMCID: PMC4455308.
Copy Download .nbib Format: NLM
Share it on

Front Psychol. 2015 Jun 04;6:708. doi: 10.3389/fpsyg.2015.00708. eCollection 2015.

A new cognitive evaluation battery for Down syndrome and its relevance for clinical trials.

Frontiers in psychology

Susana de Sola, Rafael de la Torre, Gonzalo Sánchez-Benavides, Bessy Benejam, Aida Cuenca-Royo, Laura Del Hoyo, Joan Rodríguez, Silvina Catuara-Solarz, Judit Sanchez-Gutierrez, Ivan Dueñas-Espin, Gimena Hernandez, Jordi Peña-Casanova, Klaus Langohr, Sebastia Videla, Henry Blehaut, Magi Farre, Mara Dierssen,

Affiliations

  1. Human Pharmacology and Clinical Neurosciences Research Group-Neurosciences Program, IMIM-Hospital del Mar Medical Research Institute Barcelona, Spain ; Cellular and Systems Neurobiology Research Group, Systems Biology Program, Centre for Genomic Regulation Barcelona, Spain.
  2. Human Pharmacology and Clinical Neurosciences Research Group-Neurosciences Program, IMIM-Hospital del Mar Medical Research Institute Barcelona, Spain ; Biomedical Research Centre in Physiopathology of Obesity and Nutrition (CIBEROBN) Santiago de Compostela, Spain ; CEXS, Universitat Pompeu Fabra Barcelona, Spain.
  3. Human Pharmacology and Clinical Neurosciences Research Group-Neurosciences Program, IMIM-Hospital del Mar Medical Research Institute Barcelona, Spain ; Neurofunctionality of Brain and Language Group-Neurosciences Program, IMIM-Hospital del Mar Medical Research Institute Barcelona, Spain.
  4. Fundació Catalana Síndrome de Down Barcelona, Spain.
  5. Human Pharmacology and Clinical Neurosciences Research Group-Neurosciences Program, IMIM-Hospital del Mar Medical Research Institute Barcelona, Spain ; Drug Abuse Epidemiology Research Group-Epidemiology and Public Health Program, IMIM-Hospital del Mar Medical Research Institute Barcelona, Spain.
  6. Human Pharmacology and Clinical Neurosciences Research Group-Neurosciences Program, IMIM-Hospital del Mar Medical Research Institute Barcelona, Spain.
  7. Cellular and Systems Neurobiology Research Group, Systems Biology Program, Centre for Genomic Regulation Barcelona, Spain.
  8. Fundació Privada Espai Salut Barcelona, Spain.
  9. Human Pharmacology and Clinical Neurosciences Research Group-Neurosciences Program, IMIM-Hospital del Mar Medical Research Institute Barcelona, Spain ; CEXS, Universitat Pompeu Fabra Barcelona, Spain.
  10. Human Pharmacology and Clinical Neurosciences Research Group-Neurosciences Program, IMIM-Hospital del Mar Medical Research Institute Barcelona, Spain ; Universitat Autónoma de Barcelona UDIMAS, Barcelona, Spain.
  11. Human Pharmacology and Clinical Neurosciences Research Group-Neurosciences Program, IMIM-Hospital del Mar Medical Research Institute Barcelona, Spain ; Department of Statistics and Operations Research, Universitat Politècnica de Catalunya Barcelona, Spain.
  12. Fondation Jérôme Lejeune Paris, France.
  13. Human Pharmacology and Clinical Neurosciences Research Group-Neurosciences Program, IMIM-Hospital del Mar Medical Research Institute Barcelona, Spain ; Universitat Autònoma de Barcelona, i Hospital Universitari Germans Trias i Pujol (IGTP) Barcelona, Spain.
  14. Cellular and Systems Neurobiology Research Group, Systems Biology Program, Centre for Genomic Regulation Barcelona, Spain ; Biomedical Research Centre on Rare Diseases (CIBERER) Valencia, Barcelona, Spain.

PMID: 26089807 PMCID: PMC4455308 DOI: 10.3389/fpsyg.2015.00708

Abstract

The recent prospect of pharmaceutical interventions for cognitive impairment of Down syndrome (DS) has boosted a number of clinical trials in this population. However, running the trials has raised some methodological challenges and questioned the prevailing methodology used to evaluate cognitive functioning of DS individuals. This is usually achieved by comparing DS individuals to matched healthy controls of the same mental age. We propose a new tool, the TESDAD Battery that uses comparison with age-matched typically developed adults. This is an advantageous method for probing the clinical efficacy of DS therapies, allowing the interpretation and prediction of functional outcomes in clinical trials. In our DS population the TESDAD battery permitted a quantitative assessment of cognitive defects, which indicated language dysfunction and deficits in executive function, as the most important contributors to other cognitive and adaptive behavior outcomes as predictors of functional change in DS. Concretely, auditory comprehension and functional academics showed the highest potential as end-point measures of therapeutic intervention for clinical trials: the former as a cognitive key target for therapeutic intervention, and the latter as a primary functional outcome measure of clinical efficacy. Our results also emphasize the need to explore the modulating effects of IQ, gender and age on cognitive enhancing treatments. Noticeably, women performed significantly better than men of the same age and IQ in most cognitive tests, with the most consistent differences occurring in memory and executive functioning and negative trends rarely emerged on quality of life linked to the effect of age after adjusting for IQ and gender. In sum, the TESDAD battery is a useful neurocognitive tool for probing the clinical efficacy of experimental therapies in interventional studies in the DS population suggesting that age-matched controls are advantageous for determining normalization of DS.

Keywords: Down syndrome; TESDAD neurocognitive battery; clinical trials as topic; cognition; intellectual disabilities

References

  1. Int J Geriatr Psychiatry. 2014 Oct;29(10 ):1040-8 - PubMed
  2. Res Dev Disabil. 2013 May;34(5):1770-80 - PubMed
  3. Cogn Affect Behav Neurosci. 2003 Dec;3(4):255-74 - PubMed
  4. Lancet Neurol. 2010 Jun;9(6):623-33 - PubMed
  5. Transl Psychiatry. 2012 Jul 17;2:e141 - PubMed
  6. Child Dev. 2003 Jan-Feb;74(1):75-93 - PubMed
  7. J Intellect Disabil Res. 2010 Apr;54(4):308-19 - PubMed
  8. J Cogn Neurosci. 2011 Jan;23(1):257-65 - PubMed
  9. J Int Neuropsychol Soc. 1998 Sep;4(5):474-90 - PubMed
  10. Am J Ment Retard. 2004 Nov;109(6):456-66 - PubMed
  11. Res Dev Disabil. 2010 Mar-Apr;31(2):568-76 - PubMed
  12. Br J Clin Psychol. 2006 Mar;45(Pt 1):5-17 - PubMed
  13. Behav Genet. 2006 May;36(3):355-64 - PubMed
  14. Brain. 2004 Apr;127(Pt 4):811-24 - PubMed
  15. J Intellect Disabil Res. 2002 Sep;46(Pt 6):472-83 - PubMed
  16. Res Dev Disabil. 2011 Nov-Dec;32(6):2225-34 - PubMed
  17. Cortex. 2013 Jan;49(1):232-42 - PubMed
  18. Br J Clin Psychol. 2008 Mar;47(Pt 1):1-29 - PubMed
  19. Neuropharmacology. 2013 Jan;64:2-7 - PubMed
  20. J Intellect Disabil Res. 2010 May;54(5):406-17 - PubMed
  21. Soz Praventivmed. 2005;50(5):281-91 - PubMed
  22. Am J Psychiatry. 2012 Sep;169(9):926-36 - PubMed
  23. Prog Neurobiol. 2010 May;91(1):1-22 - PubMed
  24. Acta Psychiatr Scand. 1988 Sep;78(3):369-74 - PubMed
  25. Hum Brain Mapp. 2014 May;35(5):1834-46 - PubMed
  26. Downs Syndr Res Pract. 2006 Aug;11(1):37-43 - PubMed
  27. Soc Sci Med. 2006 Feb;62(4):815-27 - PubMed
  28. Mol Nutr Food Res. 2014 Feb;58(2):278-88 - PubMed
  29. Neurologia. 2012 Jun;27(5):253-60 - PubMed
  30. Dev Neurosci. 2011;33(5):414-27 - PubMed
  31. Arch Gen Psychiatry. 2005 Dec;62(12):1360-5 - PubMed
  32. Cereb Cortex. 2001 Sep;11(9):825-36 - PubMed
  33. Int J Lang Commun Disord. 2004 Oct-Dec;39(4):423-51 - PubMed
  34. Am J Psychiatry. 2010 Jul;167(7):748-51 - PubMed
  35. Downs Syndr Res Pract. 2001 Oct;7(1):9-15 - PubMed
  36. Neuroimage. 2003 Sep;20(1):393-403 - PubMed
  37. Qual Life Res. 2009 Nov;18(9):1147-57 - PubMed
  38. J Speech Lang Hear Res. 2010 Oct;53(5):1334-48 - PubMed
  39. J Neurodev Disord. 2010 Sep 1;2(3):149-164 - PubMed
  40. Funct Neurol. 2013 Jan-Mar;28(1):19-28 - PubMed
  41. Am J Psychiatry. 2002 Jan;159(1):74-81 - PubMed
  42. Birth Defects Res A Clin Mol Teratol. 2011 Mar;91 Suppl 1:S16-22 - PubMed
  43. Neurology. 1995 Feb;45(2):356-66 - PubMed
  44. Genet Med. 2009 Sep;11(9):611-6 - PubMed
  45. Acta Neuropathol. 1990;79(6):680-5 - PubMed
  46. J Intellect Disabil Res. 1994 Jun;38 ( Pt 3):265-73 - PubMed

Publication Types